Scientific Industries (SCND) Q3 2024 earnings summary

Executive summary

• Focus on transforming into a thriving life sciences tool business with growing sales, margins, recurring revenue, and profitability.

• Net loss for Q3 2024 was $1.18M, a 46% improvement from Q3 2023, driven by cost reductions and higher revenues in both operating segments.

• Revenues for Q3 2024 increased 7.1% year-over-year to $2.77M, with growth in both Benchtop Laboratory Equipment and Bioprocessing Systems.

• Legacy Genie benchtop lab equipment business recovered, supporting investments in new growth areas.

• Vivid Pill Counter business saw strong sales growth, with a new Vivid Workstation product poised for broader market impact.

Financial highlights

• Vivid Pill Counter sales up 50% sequentially and 12% year-over-year in Q3.

• Bioprocessing segment sales up 12% year-over-year for the first nine months; U.S. bioprocessing sales up 61% year-to-date.

• Q3 2024 revenue: $2.77M (up 7.1% year-over-year); nine-month revenue: $7.90M (down 5.7% year-over-year).

• Q3 2024 net loss: $1.18M; nine-month net loss: $4.52M.

• Company-wide operating expenses reduced by over $1 million (22%) year-over-year.

Outlook and guidance

• Initial signs of relief in bioprocessing markets expected to continue into 2025.

• Hardware development for both major platforms expected to complete in coming quarters.

• Anticipation of moving from capital consumption to capital return as product-market fit is validated.

• Management does not believe current cash and expected internal cash flows are sufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.

• Plans to secure additional capital include seeking funds from management, significant shareholders, and third-party equity or debt financing.